Variable	Value
Sex, male n (%)	2 (8)
Age, years	30. 6 (10.0)
mean (SD) median (min; max)	32.0 (10; 5)
Treatment indication, n (%)
Refractory to medical therapy	14 (56)
Medication intolerance	7 (28)
Fulminant	4 (16)
BMI at enrollment, kg/m2
Mean (SD)	32.29 (5.12)
Median (min; max)	30.95 (22; 41)
CSF opening pressure at diagnosis, mmHg
Mean (SD)	357.08 (100.02)
Median	365
Pre-Stenting Meds, n (%)
ACTZ 1000 mg/d	12 (48)
ACTZ 2000 mg/d	4 (16)
ACTZ 3000 mg/d	2 (8)
ACTZ 1000 mg/bid +TPM 50mg/bid	1 (4)
ACTZ 1500 mg/d	1 (4)
ACTZ 2500 mg/d+ TPM 50 mg/d	1 (4)
ACTZ 500 mg/bid +TPM 50 mg/bid	1 (4)
ACTZ 2500 mg/d+ TPM 25 mg/d	1 (4)
TPM 100 mg/d	1 (4)
Post Stenting Meds, n (%)
None	15 (60)
ACTZ 500 mg/d	5 (20)
ACTZ 250 mg/d	3 (12)
ACTZ 750 mg/d	1 (4)
TPM 150 mg/d	1 (4)

Table 1: Demographic and clinical I characteristics and patient's medications in the study population (N=25)